Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere
Conditions
Interventions
Intervention1: NIMBATIKTAM AND LAJJALU KERAM GEL: 1. Nimbatiktam
Dose: Capsule containing 200 mg of Nimba satva twice daily after meals
Route of Administration: Oral
Anupan: Lukewarm water
Duration of
Sponsors
Central Council for Research in Ayurvedic Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex with age between 18 and 60 years. 2. Known cases of psoriasis, without psoriatic arthropathy, Exhibiting psoriatic triad â?? a. Bright pink or red lesions with pronounced edges, covered with silvery white scales, the scales can be easily separated from the lesion. b. Under the scales there appears a pinkish moist tender skin. c. With the scraping of the moist skin there appear tiny blood droplets (Auspitzâ??s sign) 3. Patients suffering from psoriasis with less than 50 % of the body surface involvement. 4. Disease duration between 3 months to 5 years. 5. V.D.R.L./ HIV/Hepatitis negative. 6. Positive histopathological finding.(Skin-biopsy) 7. Willing to participate in the study
Exclusion criteria
Exclusion criteria: 1. Generalized skin lesions, Herpes simplex, Herpes zoster, Scabies, Acne, Urticaria, and Immunological mediated skin diseases like Pempigus vulgaris, Dermatitis, herpetiformis, Guttate, Pustular, Lupus erythematous, Psoriatic arthropathy etc. 2. Patients with poorly controlled Hypertension (Blood pressure more than 160/100mm of Hg). 3. Pregnant or lactating woman. 4. Patient with uncontrolled Diabetes Mellitus (Blood sugar fasting more than 250 mg/dl). 5. Patient suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho - Neuro-endocrinal disorders, etc.). 6. Patients on medication with corticosteroids, phototherapy, biologics, antidepressants any other drugs that may have an influence on the outcome of the study. 7. Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT >3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.4 mg/dl) or uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or AIDS or STD or other concurrent severe disease. 8. Alcoholics and/or drug abusers. 9. H/o hypersensitivity to the trial drug or any of their ingredients. 10. Patients who have completed participation in any other clinical trial during the past six months. 11. Any other condition which the Investigator thinks may jeopardize the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in Psoriasis Area and Severity Index(PASI) score.Timepoint: 28th day, 56th day, 84th day, 112th day, 140th day: | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the clinical Sign & symptoms of Psoriasis Change in Dermatology life Quality Index (DLQI) QuestionnaireTimepoint: 28th day, 56th day, 84th day, 112th day, 140th day: | — |
Countries
India
Contacts
Public ContactDr G Babu
central council for research in ayurvedic sciences
Outcome results
None listed